Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Regenerx Biopharmaceuticals has received an Australian patent for the use of Ta4, its derivatives, analogues and fragments, to repair pulmonary damage resulting from pulmonary microbial infections. The patent expires in 2023.
Subscribe to our email newsletter
Ta4 is a synthetic version of a biologically active, naturally occurring peptide that has been shown, in preclinical studies, to be effective in accelerating dermal, ophthalmic, and myocardial wound healing.
David Crockford, vice president for clinical and regulatory affairs at Regenerx, said: “We are pleased to receive this patent as it expands our intellectual property portfolio by addressing potential disease indications beyond wound healing that may benefit from our drug candidates, in addition to creating a proprietary position through 2023.”